What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Testimonials


Omixon Blog

Omixon Launches Holotype HLA™ for NGS-based HLA Genotyping

Omixon announces the launch of Omixon Holotype HLA™ – a combination Assay and Software product that leverages the power of Next Generation Sequencing (NGS), for use on the Illumina® MiSeq sequencing platform. The assay and software have been optimized through …more

By Craig Funnell 0 comments

Omixon Celebrates a Successful EFI 2014

Omixon took a team of 8 to the 28th EFI (European Histocompatibility and Immunogenetics) Conference, held in Stockholm.  Omixon’s “A Team” of defenders (science nerds), midfielders (marketing bods) and strikers (sales weenies) were superbly captained by the indefatigable Craig Funnell …more

By kriszta.katona 0 comments